Influence of oligoclonal IgM specificity in multiple sclerosis disease course

Multiple Sclerosis

Volumn 14, Issue 2, 2008, Pages 183-187

  Villar, Luisa M ^a   Garcia Barragan N ^a   Espino M ^a   Roldan E ^a   Sádaba, Mc ^a   Gomez Rial J ^a   Gonzalez Porque P ^a   Alvarez Cermeno J C ^a,b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

antibodies; B lymphocytes; IgM; multiple sclerosis; oligoclonal bands; prognosis

Indexed keywords

ALBUMIN; BETA1A INTERFERON; CD5 ANTIGEN; GLATIRAMER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON BETA SERINE; MYELIN; OLIGOCLONAL BAND;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISABILITY SEVERITY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE;

ADULT; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGOCLONAL BANDS; PROGNOSIS;

EID: 43149096970     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458507082046     Document Type: Article

References (25)

1. Compston A., Coles A. Multiple Sclerosis. Lancet 2002; 359: 1221-31.
2. Ferguson B., Matyszak MK, Esiri MM, Perry VH Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.
3. Trapp BD, Peterson J., Ransohoff RM, Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
4. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17.
5. Bielekova B., Kadom N., Fisher E. et al. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005; 65: 1071-6.
6. Noseworthy JH, Lucchinetti C., Rodriguez M., Weinshenker BG Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
7. Villar LM, Masjuan J., González-Porqué P., Plaza J., Sádaba MC, Roldán E. et al. Intrathecal IgM synthesis in neurological diseases. Relationship of oligoclonal IgM and disability in MS. Neurology 2002; 58: 824-6.
8. Villar LM, Plaza J., Sádaba MC, Roldán E. et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002; 59: 555-9.
9. Villar LM, Masjuan J., González-Porqué P., Plaza J., Sádaba MC, Roldán E. et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003; 53: 222-6.
10. Villar LM, Sádaba MC, Roldán E., Masjuan J., González-Porqué P., Villarrrubia N. et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115: 187-194.
11. Perini P., Ranzato F., Calabrese M., Battistin L., Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease course in Multiple Sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 953-5.
12. McDonald WI, Compston A., Edan G., Goodkin D., Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
13. Poser CM, Paty DW, Scheinberg L., McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
14. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
15. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: The multiple sclerosis collaborative research group (MSCRG). Ann Neurol 1996; 39: 285-94.
16. Arbizu T., Alvarez-Cermeño JC, Decap G., Fernandez O., Uria DF, García-Merino A. et al. Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain. Acta Neurol Scand 2000; 102: 209-17.
17. Sádaba MC, Gonzalez-Porqué P., Masjuan J., Álvarez-Cermeño JC, Bootello A., Villar LM An ultrasensitive method for the detection of oligoclonal IgG bands. J Immunol Meth 2004; 284: 141-5.
18. Villar LM, Gonzalez-Porqué P., Masjuan J., Álvarez-Cermeño JC, Bootello A., Keir G. A sensitive and reproducible method for the detection of oligoclonal IgM bands. J Immunol Meth 2001; 258: 151-5.
19. Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000; 37: 1141-9.
20. Bongioanni P. Lymphocyte subsets in multiple sclerosis. A study with two-colour fluorescence analysis. J Neurol Sci 1996; 139: 71-7.
21. Cepok S., Jacobsen M., Schock S., Omer B., Jaekel S., Boddeker I. et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001; 124: 2169-76.
22. Cepok S., Rosche B., Grummel V., Vogel F., Zhou D., Sayn J. et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005; 128: 1667-76.
23. Gay FW, Drye TJ, Dick GW, Esiri M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Brain 1997; 120: 1461-83.
24. Barnett MH, Prineas JW Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-68.
25. Genain, CP, Canella B., Hauser SL, Raine CS Identification of the autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5: 153-4.